Brief: Point Biopharma Publishes Preclinical Data For Actinium-Labelled Pnt2001
Oct 17 (Reuters) - POINT Biopharma Global Inc PNT.O :
* POINT BIOPHARMA PUBLISHES PRECLINICAL DATA FOR
ACTINIUM-LABELLED
PNT2001, A NEXT-GENERATION PSMA LIGAND, AT EANM’S ANNUAL
CONGRESS
* POINT BIOPHARMA GLOBAL INC - TARGETING IND/CTA SUBMISSION
FOR
PNT2001 PROGRAM IN H1 2023
Source text for Eikon: ID:nGNX5ctFJZ
Further company coverage: PNT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on POINT Biopharma Global
See all newsBrief: Eli Lilly Completes Acquisition Of POINT Biopharma
Fusion Pharma gains on Bristol Myers-RayzeBio deal
Brief: Point Biopharma- Lilly Offer Expired And Not Further Extended - SEC Filing
Brief: BVF Partners Dissolves Share Stake In Point Biopharma Global
U.S. STOCKS ON THE MOVE-Biomerica, Netflix, SunPower